CluenexMarkel MKL
Markel scores weak on business quality (4.2 of 10). Here is why, in plain words, and what our sealed record shows.
Why it matters
- What Markel does
Markel Group writes specialty insurance policies and operates a diverse portfolio of industrial and service businesses through its Markel Ventures segment, generating cash flows from both underwriting profits and operating subsidiaries.
- What it does best
Markel excels at disciplined specialty underwriting combined with equity-like capital allocation via Markel Ventures, holding an ROE of 12.4% that outpaces AIG's 7.3%.
- The main risk
Underwriting volatility in specialty property and casualty lines poses a recurring threat to earnings stability if catastrophe losses spike unexpectedly.
Quality, check by check
Scored against its own industry, from company filings.
Operating margin stands at 18.6% with a net margin of 13.8%, reflecting stable underwriting returns that do not automatically expand with scale.
Its moat rests on niche underwriting expertise and customer lock-in across specialized commercial risks, landing it in the middle of the pack for sector margins at 43rd percentile.
Revenue growth is stagnant at -0.2%, fading compared to historical output as core specialty insurance top-line expansion pauses.
Debt-to-equity sits at 0.2 with interest coverage at 15x, backed by $3.9B in cash and $2.1B in free cash flow, keeping the balance sheet resilient.
Insiders
Executives and directors, from SEC Form 4 filings we read ourselves. Open market trades only; grants, option exercises and pre-planned sales left out.
No open market buys or unplanned sales by executives or directors.
Our sealed record on MKL
Verdicts appear here 30 days after we publish them; members see today's. Each one is in the nightly ledger, fingerprinted the night it was made.
The first sealed verdicts appear here on Oct 11, 2026.
Questions
Markel scores weak on the Cluenex quality check (4.2 of 10), measured against its own industry. Profitability is weak, moat weak, growth slow and financial health fair.
In the last 90 days of SEC Form 4 filings: No open market buys or unplanned sales by executives or directors.
Nov 4, 2026, after the close.
See MKL today
- Today's verdict on MKL, and why
- Fair value with cautious, base and optimistic cases
- The exact price that would change the verdict
- Which stocks each signal names, the night it fires
Cite this page: Cluenex, “Markel (MKL)”, https://cluenex.com/stocks/mkl/, data as of Oct 10, 2026.